
Release date: 2024-08-08 16:16:25 Article From: Lucius Laos Recommended: 257
Exkivity is an innovative third-representative dermal growth factor receptor (EGFR) tyrosine kinase inhibitor specifically designed for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.
Exkivity is a potent EGFR inhibitor that may cause a series of adverse reactions in the treatment of non-small cell lung cancer, among which "heart-rate-corrected QT (QTc) interval prolongation" is an adverse reaction of high concern. The QT interval is the distance on the ECG from the beginning of the QRS complex to the end of the T wave, representing the time required for the entire process of ventricular muscle depolarization and repolarization. The QTc interval is the heart rate-corrected QT interval that is used to more accurately assess changes in the QT interval.
Exkivity may lead to prolongation of the QTc interval, which increases the risk of arrhythmias, including serious arrhythmias such as torsade de pointes, which have the potential to progress to ventricular fibrillation and even be life-threatening. When treating with Exkivity, a series of precautions must be taken to reduce this risk.
Before starting treatment, doctors should perform a thorough electrocardiogram (ECG) to understand the patient's underlying QTc interval. During treatment, ECG monitoring should be done at regular intervals (eg, bi-weekly or monthly) to detect prolongation of the QTc interval in good time.
Electrolyte abnormalities are also an important factor in QTc interval prolongation, and patients need to be closely monitored for electrolyte levels, particularly potassium and magnesium concentrations.
If a significantly prolonged QTc interval is found during monitoring or if there are signs or symptoms of life-threatening arrhythmias, your doctor may recommend discontinuation of Exkivity therapy or dose adjustment. Severe QTc prolongation or arrhythmias may require permanent discontinuation of Exkivity and appropriate treatment.
Patients should pay close attention to their physical condition during the treatment and seek medical attention immediately if they have symptoms that may be related to arrhythmias, such as palpitations, chest tightness, dizziness, etc.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:2622025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:4832024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:2672025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:2772025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:2582025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3032025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:2652025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:2442025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: